High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma

Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients

“…The total concentrations of meropenem in plasma were determined using our high-performance liquid chromatography method, as reported previously [11]. In brief, plasma sample (400 ll) was transferred to an ultrafiltration device and centrifuged.…”

Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients

“…Both plasma and urine data were used for more thorough PK characterization. Because the pharmacodynamics of meropenem correlate with the time for which the free drug concentration remains above the MIC for the bacterium (fT [ MIC) [3], this study then used the developed PK model to assess the ability of meropenem regimes to attain a fT [ MIC target against common bacterial populations.Meropenem PK data were extracted from nine reports on separate studies [4][5][6][7][8][9][10][11][12] and modeled using NONMEM 6 …”

“…Meropenem PK data were extracted from nine reports on separate studies [4][5][6][7][8][9][10][11][12] and modeled using NONMEM 6…”

“…Meropenem PK data were extracted from nine reports on separate studies [4][5][6][7][8][9][10][11][12] and modeled using NONMEM 6 (ICON Development Solutions, Ellicott, MD, USA). A preliminary analysis indicated that a two-compartment model described the plasma data better than a one-compartment model.…”

Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid

“…The concentrations of IPM, MEPM, and DRPM in plasma and peritoneal fl uid were determined using high-performance liquid chromatography, as reported previously. [8][9][10] All pharmacokinetic data for each drug were fi tted to a standard three-compartment model, using the NONMEM program (version VI; ICON Development Solutions, Ellicott, MD, USA). The fi xed-effects parameters were the clearance (Cl), the volume of distribution of the central compartment (V1), the intercompartmental (centralperipheral) clearance (Q2), the volume of distribution of the peripheral compartment (V2), the intercompartmental (central-peritoneal) clearance (Q3), and the volume of Abstract This study aimed to develop breakpoints of carbapenems for intraabdominal infections, based on pharmacokinetics (PK) and pharmacodynamics (PD) at the target site.…”